Overview

Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa

Status:
Completed
Trial end date:
2019-06-30
Target enrollment:
0
Participant gender:
All
Summary
Hidradenitis suppurativa (HS) is an under-recognized and debilitating disease. Patients suffer from recurring painful abscesses and scarring in their armpits, under the breasts, groin and other areas of the body. The cause of the disease is still unknown and common treatments are only sometimes effective. Overactivity of the immune system has been associated with HS and molecules that cause inflammation have been found in the skin from people with HS. Current therapies have long-term risks including antibiotic resistance and the investigators aim to find new safe and effective therapies for HS. Hydroxychloroquine is a medication that has been used safely in other diseases for many years. The investigators believe that hydroxychloroquine has the potential to improve HS through multiple mechanisms. Patients enrolled in this study will be treated with hydroxychloroquine for 6 months. The investigators also aim to look at the blood of patients with HS to look for inflammatory molecules that we could possibly target for the treatment of HS. Blood samples will be taken at baseline and following 6 months of treatment.
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Elena Gonzalez Brant
Elena Gonzalez Brant, MD
Collaborator:
University of Pittsburgh
Treatments:
Hydroxychloroquine
Criteria
Inclusion Criteria:

- Patients with hidradenitis suppurativa Hurley stage I or II

Exclusion Criteria:

- Current systemic immunosuppression, current use of biologic medication or use of these
medications in the prior 3 months, patients with known retinal disease, hepatic
disease (HCV, cirrhosis, aspartate aminotransferase or alanine aminotransferase > 2
times the upper limit of normal), psoriasis, porphyria cutanea tarda, platelets <
50,000/ul, leukocytes <4000/ul, or Hb<8g/dl), pregnant patients or women trying to
conceive